"Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022" Published

From: Fast Market Research, Inc.
Published: Fri May 17 2013

GlobalData has released its new PharmaPoint Drug Evaluation report, "Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer's Betaseron/Betaferon (IFNB-1b), Biogen's Avonex (IFNB-1a) and Merck's Rebif (IFNB-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Full Report Details at
- http://www.fastmr.com/prod/591944_betaseronbetaferon_multiple_sclerosis_forecast.aspx?afid=303

Bayer's Betaseron (interferon beta-1b) is an SC-administered 165-amino acid glycoprotein agent approved for the treatment of RRMS and SPMS to reduce the frequency of relapses and slow the progression of disability. It is also indicated for individuals who have experienced a first clinical episode of inflammatory demyelination (CIS) to reduce the risk of developing clinically-definite MS. Betaseron was the first DMT to reach the market after gaining approval in 1993 from the US Food and Drug Administration (FDA) with Orphan Drug status. Importantly, Betaseron is also licensed as a treatment for SPMS, giving it a significant advantage over competing interferon agents. Despite already having reached its patent expiration in 2008, the drug still commands a sizable share of the MS market. Betaseron is marketed as Betaferon in Europe and in several other countries outside the US.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).


* Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Betaseron/Betaferon including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Betaseron/Betaferon for the top ten countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »